INO-3107 is a dna vaccine commercialized by Inovio Pharmaceuticals, with a leading Phase II program in Recurrent Respiratory Papillomatosis (Juvenile Laryngeal Papilloma or Laryngeal Papilloma). According to Globaldata, it is involved in 2 clinical trials, of which 1 is ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of INO-3107’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for INO-3107 is expected to reach an annual total of $6 mn by 2038 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

INO-3107 Overview

INO-3107 is under development for the prevention of recurrent respiratory papillomatosis caused by human papillomavirus type 6 and 11. The vaccine candidate is being developed based on SynCon vaccine platform technology and CELLECTRA DNA delivery technology. It is administered through intramuscular route.

Inovio Pharmaceuticals Overview

Inovio Pharmaceuticals (Inovio) is a biotechnology company that focuses on developing DNA immunotherapies and vaccines for the treatment and prevention of various cancers and infectious diseases. The company develops products based on its core SynCon DNA plasmid technology and electroporation delivery technology. Its product pipeline includes VGX-3100 for the treatment of cervical HSIL, vulvar HSIL, anal HSIL; INO-5401 for glioblastoma; INO-3107 for recurrent respiratory papillomatosis (RRP); and INO-5151 for prostate cancer. The company is also engaged in development programs in partnership with several companies and government bodies to develop therapeutics for infectious diseases such as HIV, Ebola, Zika virus, Middle East respiratory syndrome (MERS), Lassa fever and COVID-19. Inovio is headquartered in Plymouth Meeting, Pennsylvania, the US.

The company reported revenues of (US Dollars) US$1.8 million for the fiscal year ended December 2021 (FY2021), a decrease of 76% over FY2020. The operating loss of the company was US$301.2 million in FY2021, compared to an operating loss of US$119.4 million in FY2020. The net loss of the company was US$303.7 million in FY2021, compared to a net loss of US$166.4 million in FY2020. The company reported revenues of US$9.2 million for the third quarter ended September 2022, compared to a revenue of US$0.8 million the previous quarter.

For a complete picture of INO-3107’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.